UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 120

Sortiert nach

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5838-5847

2009

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2585-2592

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1124-1130

2010

Link zum Volltext

Verfügbarkeit prüfen

HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

Current cancer drug targets, 2017-01, Vol.17 (7), p.637

2017

Link zum Volltext

Verfügbarkeit prüfen

Leptomeningeal disease: current diagnostic and therapeutic strategies

Oncotarget, 2017-09, Vol.8 (42), p.73312-73328

2017

Link zum Volltext

Verfügbarkeit prüfen

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3324-3330

2008

Link zum Volltext

Verfügbarkeit prüfen

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

Journal of clinical oncology, 2010-07, Vol.28 (21), p.3416-3421

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5305-5313

2005

Link zum Volltext

Verfügbarkeit prüfen

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

Journal for immunotherapy of cancer, 2019-10, Vol.7 (1), p.265-265, Article 265

2019

Link zum Volltext

Verfügbarkeit prüfen

Erythropoietin Biology in Cancer

Clinical cancer research, 2006-01, Vol.12 (2), p.332-339

2006

Link zum Volltext

Verfügbarkeit prüfen

Modulation of Circulating Angiogenic Factors and Tumor Biology by Aerobic Training in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cancer prevention research (Philadelphia, Pa.), 2013-09, Vol.6 (9), p.925-937

2013

Link zum Volltext

Verfügbarkeit prüfen

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2502-2512

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

BMC cancer, 2019-11, Vol.19 (1), p.1032-9, Article 1032

2019

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy

American journal of roentgenology (1976), 2003-11, Vol.181 (5), p.1275

2003

Link zum Volltext

Verfügbarkeit prüfen

Embracing rejection: Immunologic trends in brain metastasis

Oncoimmunology, 2016-07, Vol.5 (7), p.e1172153-e1172153

2016

Link zum Volltext

Verfügbarkeit prüfen

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors

PloS one, 2008-01, Vol.3 (1), p.e1373-e1373

2008

Link zum Volltext

Verfügbarkeit prüfen

New Perspectives on Zoledronic Acid in Breast Cancer: Potential Augmentation of Anticancer Immune Response

Cancer investigation, 2011-10, Vol.29 (8), p.533-541

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparative Genome-Wide Screening Identifies a Conserved Doxorubicin Repair Network That Is Diploid Specific in Saccharomyces cerevisiae

PloS one, 2009-06, Vol.4 (6), p.e5830-e5830

2009

Link zum Volltext

Verfügbarkeit prüfen

Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?

Journal of clinical oncology, 2011-01, Vol.29 (1), p.e18-e20

2011

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)

Journal of clinical oncology, 2014-12, Vol.32 (35), p.3959-3966

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

Breast cancer research and treatment, 2018-08, Vol.171 (1), p.111-120

2018

Link zum Volltext

Verfügbarkeit prüfen

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

Targeted oncology, 2019-02, Vol.14 (1), p.1-12

2019

Link zum Volltext

Verfügbarkeit prüfen

HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors

Clinical cancer research, 2004-06, Vol.10 (12), p.4083-4088

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(108)

Publikationsform

Artikel
(119)
Bücher
(1)

Sprache

Englisch
(120)
Japanisch
(14)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

Leptomeningeal disease: current diagnostic and therapeutic strategies

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

Erythropoietin Biology in Cancer

Modulation of Circulating Angiogenic Factors and Tumor Biology by Aerobic Training in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy

Embracing rejection: Immunologic trends in brain metastasis

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

New Perspectives on Zoledronic Acid in Breast Cancer: Potential Augmentation of Anticancer Immune Response

Comparative Genome-Wide Screening Identifies a Conserved Doxorubicin Repair Network That Is Diploid Specific in Saccharomyces cerevisiae

Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors

Suchergebnisse filtern